Comparison of three different treatment modalities in the management of cancer cachexia

Tumori

Volumn 99, Issue 2, 2013, Pages 229-233

  Kanat, Ozkan ^a   Cubukcu, Erdem ^a   Avci, Nilufer ^a   Budak, Ferah ^b   Ercan, Ilker ^a   Canhoroz, Mustafa ^a   Olmez, Fatih ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b Immunology Unit   (Turkey)

Author keywords

Cachexia; Cancer; Eicosapentaenoic acid; Megesterol acetate; Meloxicam

Indexed keywords

APPETITE STIMULANT; BIOLOGICAL MARKER; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; MEGESTROL ACETATE; MELOXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; BODY MASS; CACHEXIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; APPETITE STIMULANTS; BIOLOGICAL MARKERS; BODY MASS INDEX; CACHEXIA; CYCLOOXYGENASE INHIBITORS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; THIAZINES; THIAZOLES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

MLCS; MLOWN;

EID: 84881227568     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900218     Document Type: Article

References (26)

1. Donohoe CL, Ryan AM, Reynolds JV: Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract, 2011: 601434, 2011.
2. Coss CC, Bohl CE, Dalton JT: Cancer cachexia therapy: a key weapon in the fight against cancer. Curr Opin Clin Nutr Metab Care, 14: 268-273, 2011.
3. Mantovani G, Madeddu C: Cancer cachexia: medical management. Support Care Cancer, 18: 1-9, 2010.
4. Fearon KC: Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer, 44: 1124-1132, 2008.
5. DeWys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med, 69: 491-497, 1980.
6. Buccheri G, Ferrigno D: Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung cancer, 34: 433-440, 2001.
7. Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS: Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 107: 260-265, 2007.
8. Berenstein EG, Ortiz Z: Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev, CD004310, 2005.
9. Mantovani G, Maccio A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med, 88: 85-92, 2010.
10. Murphy RA, Yeung E, Mazurak VC, Mourtzakis M: Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer, 105: 1469-1473, 2011.
11. Davis MP, Yavuzsen T, Kirkova J, Walsh D, Karafa M, LeGrand S, Lagman R: Validation of a simplified anorexia questionnaire. J Pain Symptom Manage, 38: 691-697, 2009.
12. Argilés JM, Olivan M, Busquets S, Lépez-Soriano FJ: Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res, 2: 27-38, 2010.
13. Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessì M, Panzone F, Contu P: Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist, 15: 200-211, 2010.
14. Madeddu C, Dessi M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Macciò A, Mantovani G: Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr, 31: 176-182, 2012.
15. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, Herdman M: Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage, 27: 360-369, 2004.
16. De Conno F, Martini C, Zecca E, Balzarini A, Venturino P, Groff L, Caraceni A: Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer, 34: 1705-1709, 1998.
17. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol, 20: 567-573, 2002.
18. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK, Novotny PJ, Christensen BJ: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol, 17: 3299-3306, 1999.
19. Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G: Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol, 11: 107-117, 2010.
20. Hamerman D: Molecular-based therapeutic approaches in treatment of anorexia of aging and cancer cachexia. J Gerontol A Biol Sci Med Sci, 57: M511-518, 2002.
21. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD: Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol, 24: 3401-3407, 2006.
22. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, Mac- Donald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B; North Central Cancer Treatment Group: An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol, 22: 2469-2476, 2004.
23. Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL: Inhibition of cyclooxygenase- 2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther, 308: 929-934, 2004.
24. Hussey HJ, Tisdale MJ: Effect of the specific cyclooxygenase- 2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer, 87: 95-100, 2000.
25. Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, Couch M: Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck, 30: 67-74, 2008.
26. Gullett NP, Mazurak VC, Hebbar G, Ziegler TR: Nutritional interventions for cancer-induced cachexia. Curr Probl Cancer, 35: 58-90, 2011.